- Home
- EVGN vs NERV Comparison
EVGN vs NERV Comparison
Compare EVGN & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGN
- NERV
- Stock Information
- Founded
- EVGN 1999
- NERV 2007
- Country
- EVGN Israel
- NERV United States
- Employees
- EVGN N/A
- NERV N/A
- Industry
- EVGN Agricultural Chemicals
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- EVGN Industrials
- NERV Health Care
- Exchange
- EVGN Nasdaq
- NERV Nasdaq
- Market Cap
- EVGN 11.6M
- NERV 12.0M
- IPO Year
- EVGN N/A
- NERV 2014
- Fundamental
- Price
- EVGN $1.24
- NERV $2.40
- Analyst Decision
- EVGN Strong Buy
- NERV Hold
- Analyst Count
- EVGN 1
- NERV 1
- Target Price
- EVGN $3.50
- NERV $5.00
- AVG Volume (30 Days)
- EVGN 55.7K
- NERV 41.1K
- Earning Date
- EVGN 08-19-2025
- NERV 08-14-2025
- Dividend Yield
- EVGN N/A
- NERV N/A
- EPS Growth
- EVGN N/A
- NERV N/A
- EPS
- EVGN N/A
- NERV 1.48
- Revenue
- EVGN $9,444,000.00
- NERV N/A
- Revenue This Year
- EVGN N/A
- NERV N/A
- Revenue Next Year
- EVGN $63.64
- NERV N/A
- P/E Ratio
- EVGN N/A
- NERV $1.53
- Revenue Growth
- EVGN N/A
- NERV N/A
- 52 Week Low
- EVGN $0.95
- NERV $1.15
- 52 Week High
- EVGN $3.35
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- EVGN 46.32
- NERV 63.18
- Support Level
- EVGN $1.26
- NERV $2.26
- Resistance Level
- EVGN $1.33
- NERV $2.47
- Average True Range (ATR)
- EVGN 0.07
- NERV 0.17
- MACD
- EVGN -0.00
- NERV 0.01
- Stochastic Oscillator
- EVGN 20.48
- NERV 75.31
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.